Beyond Air, Inc. (XAIR): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a company aims to revolutionize respiratory care using nitric oxide? Beyond Air, Inc. (XAIR), a commercial-stage medical device and biopharmaceutical company, is doing just that. With their innovative LungFit® system already FDA-approved and making strides in global markets, how does Beyond Air plan to tackle respiratory illnesses, neurological disorders, and even solid tumors, and what makes their approach unique? Keep reading to discover the history, ownership, mission, workings, and revenue generation of Beyond Air.

Beyond Air, Inc. (XAIR) History

Beyond Air, Inc. Founding Timeline

Year established

The company was established in 2011.

Original location

The company's original location was in Jericho, NY.

Founding team members

While specific names of all founding team members are not available in the provided context, Dr. Ronen Rubinfeld is a key figure as the founder.

Initial capital/funding

Information about the initial capital or funding is not available in the provided context.

Beyond Air, Inc. Evolution Milestones

Beyond Air, Inc. Transformative Moments

• FDA Approval of LungFit PH (2019): This was a pivotal moment, marking the transition from a development-stage company to a commercial entity. It validated the technology and opened up initial market opportunities.
• Commercial Launch of LungFit PH (2020): Successfully launching LungFit PH in the U.S. was crucial for establishing market presence and generating initial revenue.
• Expansion of Clinical Trials (2021): Expanding clinical trials to include viral pneumonia and other indications demonstrated the company's commitment to broadening the application of its technology.
• Focus on R&D: Continued investment in research and development has allowed the company to explore new applications for its inhaled nitric oxide technology, enhancing its long-term growth potential.

To gain further insights into the company's guiding principles, explore the Mission Statement, Vision, & Core Values of Beyond Air, Inc. (XAIR).

Beyond Air, Inc. (XAIR) Ownership Structure

Understanding the ownership structure of a company like Beyond Air, Inc. (XAIR) provides valuable insights into its governance and strategic direction. The following sections break down the company's current status, ownership distribution, and key leadership figures.

Beyond Air, Inc.'s Current Status

Beyond Air, Inc. is a public company, trading on the Nasdaq Capital Market under the ticker symbol XAIR. As a publicly traded entity, it is subject to regulatory oversight and reporting requirements, ensuring a level of transparency for investors.

Beyond Air, Inc.'s Ownership Breakdown

The ownership of Beyond Air, Inc. is distributed among various shareholders, including institutional investors, individual investors, and company insiders. As of the fiscal year 2024, the ownership breakdown can be visualized as follows:

Beyond Air, Inc.'s Leadership

The leadership team at Beyond Air, Inc. is responsible for setting the strategic direction and overseeing the company's operations. The key members include:

• Steve Lisi: Chairman and Chief Executive Officer
• Douglas Larson: Chief Financial Officer

These individuals, along with other members of the executive team, bring a wealth of experience in the pharmaceutical and medical device industries, guiding the company's efforts in developing and commercializing innovative therapies. For insights into the company's financial health, check out: Breaking Down Beyond Air, Inc. (XAIR) Financial Health: Key Insights for Investors

Beyond Air, Inc. (XAIR) Mission and Values

Beyond Air is dedicated to revolutionizing the treatment of respiratory diseases with innovative therapies and diagnostic tools. The company's core values center on improving patient outcomes and addressing unmet medical needs in the field of respiratory care.

Beyond Air's Core Purpose

Official mission statement

Beyond Air's mission statement, as detailed on their website, is: 'To improve lives through innovative therapies and diagnostic tools for respiratory diseases, transforming the standard of care.' Mission Statement, Vision, & Core Values of Beyond Air, Inc. (XAIR).

• Focus on innovation: The company emphasizes the development of novel therapies and diagnostic tools.
• Commitment to respiratory diseases: The mission is specifically targeted at improving the treatment of respiratory conditions.
• Improving lives: The ultimate goal is to enhance the quality of life for patients suffering from these diseases.

Vision statement

Beyond Air envisions becoming a leader in respiratory care by:

• Setting new standards: Aiming to transform the current approaches to treating respiratory diseases.
• Expanding treatment options: Providing a broader range of effective therapies.
• Advancing diagnostic capabilities: Developing tools that allow for earlier and more accurate detection of respiratory conditions.

Company slogan/tagline

While specific slogans or taglines can evolve, Beyond Air's communications often highlight:

• Innovation in respiratory care: Emphasizing their commitment to pioneering new solutions.
• Improving patient outcomes: Focusing on the tangible benefits of their therapies for patients.
• Transforming respiratory treatment: Positioning themselves as a catalyst for change in the field.

Beyond Air, Inc. (XAIR) How It Works

Beyond Air, Inc. operates by developing and commercializing a nitric oxide (NO) generator and delivery system, LungFit PH, to treat respiratory conditions. The company focuses on using inhaled nitric oxide (iNO) to target the acute and chronic respiratory diseases, and it emphasizes local manufacturing and supply chain control.

[Company's] Product/Service Portfolio

[Company's] Operational Framework

Beyond Air, Inc.'s operational framework revolves around several key areas:

• Research and Development: Continues to invest in the development and refinement of its nitric oxide delivery technology and exploring new applications for iNO therapy.
• Manufacturing: Focuses on local manufacturing and supply chain control to ensure product quality and availability.
• Clinical Trials: Conducts clinical trials to demonstrate the safety and efficacy of LungFit PH for various respiratory conditions.
• Regulatory Approvals: Actively pursues regulatory approvals from agencies like the FDA to market and sell its products.
• Commercialization: Markets and sells LungFit PH to hospitals and other healthcare providers.

[Company's] Strategic Advantages

Beyond Air, Inc. possesses several strategic advantages that contribute to its market position:

• Proprietary Technology: The LungFit PH system utilizes a unique technology to generate nitric oxide from ambient air, eliminating the need for bulky and expensive compressed gas cylinders.
• Versatile Applications: iNO therapy has potential applications in a wide range of respiratory conditions, providing Beyond Air with multiple avenues for growth.
• Strong Intellectual Property: The company has a portfolio of patents protecting its technology and products.

For more insights into the company's financial standing, read this article: Breaking Down Beyond Air, Inc. (XAIR) Financial Health: Key Insights for Investors

Beyond Air, Inc. (XAIR) How It Makes Money

The company generates revenue primarily through the sale of its LungFit PH system and related services, which is used to deliver inhaled nitric oxide (iNO) for the treatment of pulmonary hypertension and other respiratory conditions.

Revenue Breakdown

Business Economics

The business economics of the company are influenced by several factors:

• Pricing Strategy: The company employs a premium pricing strategy for its LungFit PH system, reflecting its innovative technology and clinical benefits. The pricing is also influenced by the cost of goods sold, research and development expenses, and market demand.
• Economic Fundamentals: The demand for the company's products is driven by the prevalence of pulmonary hypertension and other respiratory diseases, as well as the increasing adoption of iNO therapy in healthcare settings. Reimbursement policies from healthcare providers and government agencies also play a crucial role in the economic viability of the business.
• Market Dynamics: Competition from alternative therapies and the entry of new players in the iNO delivery market can impact the company's market share and profitability. Strategic partnerships, collaborations, and acquisitions can help the company strengthen its competitive position and expand its market reach.

Financial Performance

Key aspects of the company's financial performance include:

• Revenue Growth: The company has experienced significant revenue growth in recent years, driven by increasing sales of the LungFit PH system and related services. For example, total revenues increased by 144% to $2.2 million for the fiscal year ended March 31, 2024, compared to $0.9 million for the fiscal year ended March 31, 2023.
• Gross Margin: The company's gross margin has improved due to economies of scale and increased production efficiency. For the year ended March 31, 2024, gross profit was $0.4 million, compared to a gross loss of $0.4 million for the year ended March 31, 2023.
• Operating Expenses: The company's operating expenses include research and development, sales and marketing, and general and administrative costs. These expenses are necessary to support the company's growth initiatives and expand its market presence. Operating expenses increased to $19.9 million for the year ended March 31, 2024, from $17.1 million for the year ended March 31, 2023, primarily due to increased sales and marketing expenses and personnel costs.
• Net Loss: The company has historically incurred net losses as it invests in research and development and commercialization activities. Net loss was $19.5 million for the year ended March 31, 2024, compared to $17.5 million for the year ended March 31, 2023.
• Liquidity and Capital Resources: As of March 31, 2024, the company had cash and cash equivalents of $7.8 million. The company has relied on a combination of equity and debt financings to fund its operations and expects to continue to do so in the future.

To gain more insight into the company's values, check out: Mission Statement, Vision, & Core Values of Beyond Air, Inc. (XAIR).

Beyond Air, Inc. (XAIR) Market Position & Future Outlook

Beyond Air, Inc. is focused on developing innovative therapies using its LungFit® platform to deliver inhaled nitric oxide (iNO) for various respiratory conditions. As of April 2025, the company's market position is characterized by its niche focus on iNO delivery technology and its potential to address unmet needs in respiratory care. The future outlook hinges on successful clinical trials, regulatory approvals, and market adoption of its LungFit® platform.

Competitive Landscape

Opportunities & Challenges

Industry Position

Beyond Air operates within the broader respiratory therapy market, specifically targeting inhaled nitric oxide (iNO) delivery. Here's a snapshot of their industry positioning:

• Niche Player: Beyond Air distinguishes itself through its innovative LungFit® platform, designed for efficient iNO delivery and potential use in various settings, including at-home treatment.
• Technology Focus: The company's primary strength lies in its proprietary technology, which could offer advantages over traditional iNO delivery methods.
• Market Access: Overcoming challenges related to market access and reimbursement will be crucial for broader adoption of LungFit®.

For insights into the financial health of Beyond Air, Inc., you can explore this analysis: Breaking Down Beyond Air, Inc. (XAIR) Financial Health: Key Insights for Investors